Gopal, Ajay K.

Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity

Jacobson, C. A., Hunter, B. D., Redd, R., Rodig, S. J., Chen, P.-H., Wright, K., Lipschitz, M., Ritz, J., Kamihara, Y., Armand, P., et al. (2020) · Journal of Clinical Oncology

CAR-T cell therapy researchLymphoma Diagnosis and Treatment

Cited by 352

Phase i study of single-agent utomilumab (PF-05082566), a 4-1bb/cd137 agonist, in patients with advanced cancer

Segal, N. H., He, A. R., Doi, T., Levy, R., Bhatia, S., Pishvaian, M. J., Cesari, R., Chen, Y., Davis, C. B., Huang, B., et al. (2018) · Clinical Cancer Research

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 267

Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus 131I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016

Shadman, M., Li, H., Rimsza, L., Leonard, J. P., Kaminski, M. S., Braziel, R. M., Spier, C. M., Gopal, A. K., Maloney, D. G., Cheson, B. D., et al. (2018) · Journal of Clinical Oncology

Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research

Cited by 86